| THURSDAY, FEBRUARY 04, 2010 |
| 4:00 PM | Alkermes Reports Third Quarter Fiscal 2010 Financial Results - BusinessWire |
 |
| 8:30 AM | Alkermes Unveils Long-Acting Injectable Proprietary Platform for Treatment of Schizophrenia and Other CNS Disorders - BusinessWire |
|
| MONDAY, FEBRUARY 01, 2010 |
| 4:00 PM | Alkermes' Corporate Presentation to be Webcast at the BIO CEO & Investor Conference - BusinessWire |
|
| THURSDAY, JANUARY 28, 2010 |
| 4:00 PM | Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2010 - BusinessWire |
|
| TUESDAY, JANUARY 26, 2010 |
| 8:33 AM | Byetta LAR Will Become Decision Resources' New Clinical Gold Standard in 2013 for the Treatment of Type 2 Diabetes - PR Newswire |
|
| WEDNESDAY, JANUARY 06, 2010 |
| 4:00 PM | Alkermes' Corporate Presentation to be Webcast at the 28th Annual JPMorgan Healthcare Conference - BusinessWire |
|
| TUESDAY, DECEMBER 15, 2009 |
| 8:15 AM | Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study - BusinessWire |
|
| 8:00 AM | Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study - PR Newswire |
|
| TUESDAY, DECEMBER 08, 2009 |
| 4:00 PM | Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank Biotech Boston Confab - BusinessWire |
|
| THURSDAY, DECEMBER 03, 2009 |
| 12:00 PM | Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma - BusinessWire |
|
